Document is current
Any future updates will be listed below
-
Authors
Winkelmann, Alexander
Loebermann, Micha http://orcid.org/0000-0002-3453-8998
Barnett, Michael
Hartung, Hans-Peter
Zettl, Uwe K.
- License Information
-
More Information
Article History
Accepted: 10 March 2022
First Online: 6 April 2022
Competing interests
: A.W. reports personal fees from Alexion, Biogen, Celgene, Merck, Novartis, Sanofi, Roche and Teva that are not directly related to the manuscript. M.L. reports institutional funding from Sanofi Pasteur and personal fees from AbbVie, Bayer, Bristol Myers Squibb, Merck Healthcare and Pfizer that are not directly related to the manuscript. M.B. reports institutional funding from Alexion, Biogen, BMS, Merck, Novartis, and Roche and personal fees from Biogen and Novartis that are not directly related to the manuscript. H.-P.H. reports personal fees from Bayer Healthcare, Biogen, Celgene BMS, GeNeuro, Merck, Novartis, Roche, TG Therapeutics and VielaBio that are not directly related to the manuscript. U.K.Z. reports personal fees from Alexion, Almirall, Bayer, Biogen, Janssen, Merck Serono, Novartis, Octapharm, Roche, Sanofi Genzyme, and Teva as well as grants from the European Union, German Federal Ministry of Education and Research, German Federal Ministry for Economic Affairs and Climate Action, and Deutsche Forschungsgemeinschaft that are not directly related to the manuscript.
Free to read: This content has been made available to all.
